Key result
Pioglitazone treatment in patients with type 2 diabetes on hemodialysis reduced mean HbA1c by 1.52% at 12 months without causing serious adverse effects.
Why the study?
Does pioglitazone improve glucose control and is it safe in T2DM patients receiving long term hemodialysis?
Cohort (n=50)
No
Does pioglitazone improve glucose control and is it safe in T2DM patients receiving long term hemodialysis?
Adding pioglitazone to standard hypoglycemic agents in T2DM patients on hemodialysis significantly improves glucose control and is well tolerated without major safety issues.
Answers are grounded in this paper and cite their sources.
May support pioglitazone in T2DM-ESRD on hemodialysis; hypothesis-generating, needs prospective validation.
Background: Type 2 diabetes mellitus (T2DM) frequently causes end stage renal disease (ESRD). Glucose-lowering treatment options for patients with T2DM with ESRD are limited. Thiazolidinedione is an oral glucose lowering agent used to treat patients with ESRD. We evaluated the potential for pioglitazone in combination with other hypoglycemic medications among patients with T2DM receiving long term hemodialysis Objectives: To evaluate the safety and efficiency of pioglitazone among patients with ESRD receiving hemodialysis. Methods: The retrospective study was conducted in the outpatient clinic of Phramongkutklao Hospital during 2006 and 2015. HemoglobinA1C (HbA1c), fasting plasma glucose (FPG), body weight, hematocrit and history of diagnosed chronic heart failure were evaluated after starting medication and 1 year of follow-up Results: Data for hemodialysis patients on pioglitazone were analyzed (n=50). Mean FPG changes from baseline were -28.8+-80.0 mg/dL after 12 weeks (p=0.018) and -59.2+-80.0 mg/dL after 12 months of treatment (p < 0.001). Mean HbA1c changes from baseline were also-0.25+-1.62% after 12 weeks (p=0.318) and -1.52+-1.77% after 12 months of treatment (p < 0.001). The differences in mean body weight (63.2+-13.0 kg; p= 0.139) and hematocrit (33.4+-5.5 vs. 33.6+-5.3; p= 0.929) at baseline and 12 months were not significant, while episodes of congestive heart failure were low (4%). No serious adverse effects such as hypoglycemia with hospitalization or liver failure were observed in any of the patients Conclusion: These data suggest that adding pioglitazone to standard hypoglycemic agents patients with T2DM undergoing hemodialysis glucose control and was well tolerated
No takes yet. Share an insight, caveat, or question.
Limwatthana et al. (2018) conducted a cohort in Type 2 diabetes mellitus with end stage renal disease (n=50). Pioglitazone was evaluated on Mean HbA1c change from baseline at 12 months (p=< 0.001). Pioglitazone treatment in patients with type 2 diabetes on hemodialysis reduced mean HbA1c by 1.52% at 12 months without causing serious adverse effects.
Synapse has enriched 10 related papers. Consider them for comparative context: